The LDLR gene helps explain how the body clears LDL particles from blood, but an LDLR variant is not automatically a diagnosis. Interpretation requires the exact change, reliable evidence and a relevant clinical picture. This guide connects the biology to a practical method for reading reports and research.
In this guide: What does LDLR do? · How does LDLR relate to familial hypercholesterolemia? · Six details to extract from a report · What evidence supports classification? · An evidence-reading exercise · How should I use ClinVar? · Questions for clinicians and researchers
What does LDLR do?
LDLR encodes the LDL receptor, a protein that binds LDL particles at the cell surface and helps bring them into cells. Receptors can return to the surface for further uptake. Liver cells play a major role in clearing circulating LDL; reduced receptor number or impaired function can raise LDL cholesterol. [1]
Some disease-causing LDLR variants reduce receptor production, while others interfere with its function. This mechanism explains why different experiments may measure different aspects of a variant’s effect. The diagram below is a simplified pathway, not a molecular structure or a quantitative prediction. [1]
How does LDLR relate to familial hypercholesterolemia?
A pathogenic variant in one LDLR copy can cause a dominant form of familial hypercholesterolemia. Disease-causing changes affecting both copies can produce a more severe presentation, often from childhood. The broader FH spectrum also includes other genes and genetic combinations, so a negative LDLR-only test is not equivalent to a complete investigation of inherited high cholesterol. [2]
The companion familial hypercholesterolemia guide covers diagnosis, family screening and preparing for care. Here the narrower question is whether a particular LDLR finding has sufficient evidence to explain the relevant phenotype. The gene’s established disease association does not make every change within it harmful. [3]
Six details to extract from a report
- Exact sequence description: retain transcript and version, DNA and protein notation, and the laboratory’s identifier.
- Variant type: is it a single-base change, a small insertion/deletion, a splice-related finding or a larger copy-number change?
- Zygosity and phase: how many gene copies are affected, and is the arrangement established when multiple findings are present?
- Clinical classification: record the category, disease context and date rather than paraphrasing “uncertain” as “positive.”
- Assay coverage: note which regions and variant classes were assessed and which were not.
- Clinical context: keep untreated or historical LDL measurements, treatment history and documented family findings available to the interpreting team.
Use these fields as a transcription checklist. They are not points in a do-it-yourself pathogenicity score. A specialist should resolve conflicts between the report, database assertions and phenotype.
What evidence supports classification?
The ClinGen FH Variant Curation Expert Panel developed LDLR-specific adaptations of the ACMG/AMP framework. These address evidence such as population frequency, clinical observations, segregation, predicted loss of function and functional studies. The strength assigned to an item depends on defined criteria; counting several weak predictions as independent proof is inappropriate. [4]
Check the ClinGen LDLR specification record when preparing a professional assessment, and record the version used. This article does not reproduce a current scoring rule set. It is a reading guide for understanding why a classification requires documented evidence. [5]
A functional assay may measure receptor expression, LDL binding, uptake or another relevant endpoint. Ask whether the assay actually isolates the variant’s effect, includes suitable controls and has been validated for the intended inference. A result from cells containing several relevant variants can be difficult to attribute to one change. [4]
An evidence-reading exercise
Hypothetical example: a paper reports reduced LDL uptake in cells carrying a candidate variant. Before writing “the variant causes FH,” make four columns: what the cells expressed; the measured endpoint; the comparator and controls; and the clinical or family evidence. Leave a column blank when the paper does not answer it. This exposes the missing information without inventing a conclusion.
For further context, read functional variant assays and population reference data. A research finding may contribute to interpretation without being sufficient on its own.
How should I use ClinVar?
The variant research assistant creates search links and a downloadable evidence worksheet. In ClinVar, confirm the exact variant, examine the condition-specific assertion and check the review status. An expert-panel assessment has a distinct review designation; a star count is not a numerical disease-risk estimate. Read dates and supporting evidence rather than relying only on the top-line label. [6]
If interpretations differ, use our guide to ClinVar discordance to frame questions for the reporting laboratory. An online search should not silently replace a signed clinical report.
Questions for clinicians and researchers
- Does the reported variant match the source record at the sequence and transcript level?
- Was the classification made using an applicable, identified framework?
- Which independent evidence items support or challenge it?
- Would family data or a different assay meaningfully resolve uncertainty?
- What remains necessary for clinical care regardless of the molecular result?
Use the research tools to document a search for LDLR evidence and the care finder for genetics support. For family follow-up, read cascade testing. A specialist should select any additional testing and interpret the result with the lipid history.
Educational information. No patient-specific classification, risk calculation or prescription is provided.